FDA approves wider range of treatments for cancer drug

A drug previously approved to treat different skin cancers recently got a Food and Drug Administration greenlight to treat a few more.


Dr. Davor Vugrin, a hematologist and oncologist in Lubbock, said Keytruda already proved to be effective against several skin cancers. The FDA’s approval now includes treatment for types of colorectal cancer, gastrointestinal cancer, breast cancer, prostate cancer, bladder cancer, thyroid cancer and more.

 

The FDA granted an accelerated approval of Keytruda in May to treat tumors that originate from specific genetic biomarkers.

 

A press release from the FDA says about 39.6 percent of the 149 patients who participated in clinical trials for Keytruda showed a complete or partial tumor shrinkage. The response lasted for six months or more for about 78 percent of those patients, according to the press release.

 

“It’s quite an exciting drug,” Vugrin said.

 

Cancer treatment drugs have traditionally been approved by the FDA based on their location on the body, Vugrin said. This is the first time a drug has received FDA approval based on a genetic feature.

 

Dr. Patrick Reynolds, professor and director of the cancer center for the Texas Tech’s Health Sciences Center, said the accelerated approval means responses in the clinical trials were favorable.

 

It’s not unusual for drugs to be placed in the accelerated approval track, he said. Keytruda is unique.

 

It works by targeting the root of a genetic-based cancer and blocks T cells in the body from allowing it to replicate, he said.

 

T cells are an essential part of the immune system, Reynolds said.

 

“T cells are the immune cells in our body that recognize cells that are not supposed to be there,” he said. “If you transplant tissue from somebody else in you, that’s what’s going to reject it.”

 

When a mutation slips into a DNA strand, it often leads to cancer, he said.

 

“When we get mutations, you don’t usually get Wolverine or X-Men,” Reynolds said. “You get cancer.”

 

That’s why T cells are important in controlling cancers, he said.

 

Vugrin said Keytruda targets the T cells and makes them aware of the cancer and blocks them from aiding in the production of more cancer cells.

 

“The basic mechanism of how it works is by sort of helping the immune system to fight the cancer cell,” Vugrin said.

 

Keytruda has been effective in treating skin cancers like melanoma, he said. It’s also been approved to treat lung cancers and colorectal cancers.

Related Stories

38th Student Research Week Successful at Showcasing Secrets of Immune Defense

Student researchers at TTUHSC had the opportunity to showcase their presentation skills at the 38th Annual Student Research Week Feb. 25 – 27.

Celebrating Veterans: TTUHSC’s General Martin Clay’s Legacy of Service and Leadership

From his initial enlistment in the Army National Guard 36 years ago to his leadership in military and civilian health care management roles, Major General Martin Clay’s career has been shaped by adaptability, mission focus and service to others.

Texas Tech University Health Sciences Center School of Nursing Named Best Accelerated Bachelor of Science in Nursing Program in Texas

The TTUHSC School of Nursing Accelerated Bachelor of Science in Nursing (BSN) program has been ranked the No. 1 accelerated nursing program in Texas by RegisteredNursing.org.

Recent Stories

Education

From Backpacks to White Coats

TTUHSC School of Medicine Admissions Office team members delivered critical school supplies worth nearly $6,500 in total on Thursday, Aug. 6, to Bayless Elementary School.

Education

TTUHSC School of Medicine Students Receive First White Coat

The TTUHSC School of Medicine Class of 2030 received their first white coat and pledged their commitment to the medical profession at the White Coat Ceremony today.

Research

TTUHSC Professor Reflects on Decades of Research Benefitting Thousands of Families

After nearly 50 years with the university, Samuel Prien, Ph.D., has been packing up his office in preparation for retirement in August. Although he’s moving on, his impact at TTUHSC will remain.